Literature DB >> 20854202

Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).

Pierre De Beaudrap1, Mouhamadou Baila Diallo, Roland Landman, Ndeye Fatou Guèye, Ibrahima Ndiaye, Assane Diouf, Coumba Toure Kane, Jean-Francois Etard, Pierre-Marie Girard, Papa Salif Sow, Eric Delaporte.   

Abstract

To describe and compare the changes in renal function between HIV-1 infected adult patients receiving antiretroviral therapy (ART) with and without tenofovir (TDF). The population consisted of 40 patients starting a TDF-containing regimen and 388 patients starting regimen not containing TDF, and followed during 42 months. The estimated glomerular filtration rate (eGFR) was calculated using the Cockroft-Gault and MDRD equations and modeled separately for the first 12 months and the subsequent period. Between baseline and 12 months, the eGFR decreased significantly in patients receiving TDF (-10.40 ml/min), whereas it increased in the other +4.33 ml/min). A significant variability in the eGFR trajectories of patients receiving TDF was observed; 12 (30%) of them experienced a persistent decrease, 5 (12%) had an initial transient increase, and 23 (58%) a steady slow increase in eGFR. The characteristics at baseline of the patients with persistent decrease were not different from the other patients but their immune reconstitution was impaired. After 12 months, patients receiving TDF experienced a higher rate of transition from mild renal impairment (60-90 ml/min/1.73 m(2)) to moderate renal impairment (30-60 ml/min/1.73 m(2)) when compared with patients not receiving TDF. A significant though moderate decline in the renal function was observed in one-third of the patients receiving TDF compared to patients not receiving TDF. Moreover, this impairment was persistent after the first year of treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20854202     DOI: 10.1089/aid.2009.0261

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  15 in total

Review 1.  Renal disease in HIV-infected individuals.

Authors:  John Phair; Frank Palella
Journal:  Curr Opin HIV AIDS       Date:  2011-07       Impact factor: 4.283

Review 2.  Nephrology in Africa--not yet uhuru.

Authors:  Charles R Swanepoel; Nicola Wearne; Ikechi G Okpechi
Journal:  Nat Rev Nephrol       Date:  2013-08-20       Impact factor: 28.314

3.  Effect of Tenofovor Diproxil Fumarate on Renal Function and Urinalysis Abnormalities in HIV-Infected Cameroonian Adults.

Authors:  Carlos Fritzsche; Jens Rudolph; Barbara Huenten-Kirsch; Christoph J Hemmer; Robert Tekoh; Pius B Kuwoh; Aenne Glass; Emil C Reisinger
Journal:  Am J Trop Med Hyg       Date:  2017-11       Impact factor: 2.345

Review 4.  Renal issues in HIV infection.

Authors:  Robert C Kalayjian
Journal:  Curr HIV/AIDS Rep       Date:  2011-09       Impact factor: 5.071

5.  Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Gregory M Lucas; Michael J Ross; Peter G Stock; Michael G Shlipak; Christina M Wyatt; Samir K Gupta; Mohamed G Atta; Kara K Wools-Kaloustian; Paul A Pham; Leslie A Bruggeman; Jeffrey L Lennox; Patricio E Ray; Robert C Kalayjian
Journal:  Clin Infect Dis       Date:  2014-09-17       Impact factor: 9.079

Review 6.  Kidney disease in children and adolescents with perinatal HIV-1 infection.

Authors:  Rajendra Bhimma; Murli Udharam Purswani; Udai Kala
Journal:  J Int AIDS Soc       Date:  2013-06-18       Impact factor: 5.396

7.  Nephrotoxicity of HAART.

Authors:  Robert Kalyesubula; Mark A Perazella
Journal:  AIDS Res Treat       Date:  2011-08-15

Review 8.  Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?

Authors:  N Kumarasamy; Atul Patel; Sanjay Pujari
Journal:  Indian J Med Res       Date:  2011-12       Impact factor: 2.375

9.  Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.

Authors:  Takeshi Nishijima; Hiroyuki Gatanaga; Hirokazu Komatsu; Kunihisa Tsukada; Takuro Shimbo; Takahiro Aoki; Koji Watanabe; Ei Kinai; Haruhito Honda; Junko Tanuma; Hirohisa Yazaki; Miwako Honda; Katsuji Teruya; Yoshimi Kikuchi; Shinichi Oka
Journal:  PLoS One       Date:  2012-01-05       Impact factor: 3.240

10.  Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012.

Authors:  Philippe Morlat; Alexandre Vivot; Marie-Anne Vandenhende; Frédéric-Antoine Dauchy; Julien Asselineau; Edouard Déti; Yann Gerard; Estibaliz Lazaro; Pierre Duffau; Didier Neau; Fabrice Bonnet; Geneviève Chêne
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.